

AD _____

Award Number: DAMD17-01-1-0542

TITLE: BRCA2 is an Essential Component of the Rad51-dependent DNA Repair Complex

PRINCIPAL INVESTIGATOR: David J. Chen, Ph.D.

CONTRACTING ORGANIZATION:

Ernest Orlando Lawrence Berkeley National Laboratory
Berkeley, California 94701

REPORT DATE: July 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030109 048

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 2002	3. REPORT TYPE AND DATES COVERED Final (1 Jul 01 - 30 Jun 02)		
4. TITLE AND SUBTITLE BRCA2 is an Essential Component of the Rad51-dependent DNA Repair Complex		5. FUNDING NUMBERS DAMD17-01-1-0542		
6. AUTHOR(S) David J. Chen, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Ernest Orlando Lawrence Berkeley National Laboratory Berkeley, California 94701 Email:		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) The BRCA2 gene is associated with hereditary tendency to breast cancer. Mutations in BRCA2 cause a dominantly inherited predisposition to breast cancer. Recent evidence has indicated that BRCA2 protein plays a role in genome stability and in DNA repair mediated by homologous recombination. The BRCA2 protein has been shown to physically interact with Rad51, the key protein for DNA recombinational repair. In these BRCA2-deficient cells, formation of Rad51 foci is severely impaired. The evidence for the functions of BRCA2 in DNA repair has suggested a new concept for their role in predisposition to breast cancer. BRCA2 consists of two Rad51-binding domains, eight BRC repeats and a C-terminal region. These eight conserved BRC repeats (designated as BRC1 to BRC8), located in the central portion of the protein, are encoded by exon 11 and cover nearly a third of the protein. To demonstrate that BRCA2 is an essential component of the Rad51-dependent DNA repair complex and understand how BRCA2 regulates homologous recombinational repair (HRR), we have made construct of BRC1-4, BRC5-8 and BRC1-8 fragments of BRCA2 and to determine how it would affect the complex formation of Rad51 paralogs and in vitro biochemical activities of Rad51.				
14. SUBJECT TERMS breast cancer, BRCA2, DNA repair complex			15. NUMBER OF PAGES 10	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	


Table of Contents

Cover.....	1
SF 298	2
Table of Contents	3
Introduction	4
Body.....	4
Conclusions	8
Key Research Accomplishments.....	8
Reportable Outcomes	9
References.....	9
Appendices.....	n/a

Introduction

The BRCA2 gene is associated with hereditary tendency to breast cancer (reviewed in [1, 2]). Mutations in BRCA2 cause a dominantly inherited predisposition to breast cancer. Recent evidence has indicated that BRCA2 protein plays a role in genome stability and in DNA repair mediated by homologous recombination. The BRCA2 protein has been shown to physically interact with Rad51 [3-6], the key protein for DNA recombinational repair. Cells lacking BRCA2 function are hypersensitive to ionizing radiation and exhibit defective DNA repair [7-9]. In these BRCA2-deficient cells, formation of Rad51 foci is severely impaired. The evidence for the functions of BRCA2 in DNA repair has suggested a new concept for their role in predisposition to breast cancer.

The BRCA2 gene encodes a large protein of 3418 amino acids with a molecular weight of 384-kDa [10, 11]. This protein consists of two Rad51-binding domains, eight BRC repeats [3] and a C-terminal region [4, 5, 15]. These eight conserved BRC repeats (designated as BRC1 to BRC8) [12], located in the central portion of the protein, are encoded by exon 11 and cover nearly a third of the protein. Since the very large size of BRCA2 might hamper attempts to obtain the full-length protein, we therefore focus our efforts on the BRC repeats, which are the known functional domains for Rad51-binding of BRCA2. The domain constructs used in our study are listed in Figure 1. Our aim is to investigate how BRCA2 regulates homologous recombinational repair (HRR), mainly its effects on the complex formation of Rad51 paralogs and *in vitro* biochemical activities of Rad51 [16-18].



Body

Specific aim 1. To determine whether BRCA2 or BRC repeats of BRCA2 protein forms a stable complex with Rad51 paralogs. Our results using a baculovirus co-expression system and Ni-NTA pull-down experiments have supported that Rad51 and five Rad51 paralogs (Rad51B, Rad51C, Rad51D, XRCC2 and XRCC3) [19-25] interact simultaneously and form a novel complex. We propose to use these strategies to demonstrate that BRCA2 is an essential component in the Rad51-dependent recombinational complex, interacting with Rad51 to form a stable complex with Rad51 paralogs and to facilitate assembling of the complex formation.

Final results:

However, more recent evidence supported that the five Rad51 paralogs form four types of multiprotein complex in human cells, including Rad51B-Rad51C, Rad51D-XRCC2, XRCC3-Rad51C and Rad51B-

Rad51C-Rad51D-XRCC2 [26-28], instead of a single five-protein complex. Our *in vitro* evidence further showed the complex formation of Rad51-Rad51C-Rad51B (Figure 2). We therefore changed our aim to test whether BRCA2 forms a stable complex with Rad51-Rad51C-Rad51B. We would like to demonstrate that BRCA2 is an essential component in the Rad51-dependent DNA repair complex, interacting with Rad51 to form a stable complex with Rad51C-Rad51B and to facilitate assembling their complex formation. The Ni-NTA pull-down and gel filtration have been using to reach this goal.

We have used the baculovirus expression system to co-express BRCA2 fragments with Rad51-Rad51C-Rad51B multiprotein complex. The BRC1-4, BRC5-8 and BRC1-8 fragments have been PCR amplified using our BRCA2 full-length cDNA as a template, and individually constructed into a 6xHis-tagged baculoviral vector.

We have already co-expressed the 6xHis-tagged BRC1-4 (or BRC1-8) domain with untagged Rad51, Rad51B and Rad51C in Sf9 cells. The expression of each protein was confirmed by Western Blotting using either α -BRC4 (aa1323-1346) or α -BRC5 (aa1651-1821) antibody and α -Rad51, α -Rad51B, and α -Rad51C antibody. The Ni-NTA magnetic beads will be used to pull down the 6xHis-tagged BRC fragments and whether Rad51, Rad51B and Rad51C simultaneously associates with the BRC proteins will be determined. A gel filtration column will further used to run the co-purified sample for determining the formation of a native protein complex.




Figure 2. Complex formation of Rad51-Rad51C-Rad51B *in vitro*. A) Ni-NTA pull-down experiments using baculovirus co-expressed insect cells: lane 1, uninfected Sf9 cell extract; lane 2, Sf9 singly infected with 6x(His)-tagged Rad51B; lane 3, Sf9 doubly co-infected; and lane 4, Sf9 triply co-infected. Each gel was run in triplicate, and three Western blots were done, probing with three different antibodies. B) Ni-NTA pull-down experiments using purified Rad51, Rad51B and Rad51C proteins. Rad51B and Rad51C were mixed (molar ratio = 1:1) with increasing amounts of Rad51 in the presence of 50 μ g/ml of ethidium bromide. The pull-down samples were subjected to Western blot analysis with Rad51, Rad51B or Rad51C antibody.

Specific aim 2. To determine whether BRCA2 or BRC repeats of BRCA2 protein regulates the biochemical activities of Rad51. The direct interaction between BRCA2 and Rad51 has been demonstrated by immunoprecipitation and by a yeast two-hybrid assay [3-6]. However, it is not known how the interaction regulates homologous recombinational repair (HRR). Recent evidence [29] for BRC3 and BRC4 inhibition of nucleoprotein filament formation by Rad51 with DNA implies a role for BRCA2 in mediating the action of Rad51. We therefore propose to investigate the hypothesis that the BRCA2 protein functions to control the actions of Rad51 by directly modulating the biochemical activities of Rad51 — DNA binding, ATPase, and strand pairing and transfer — through binding to Rad51, and thereby consequently influences HRR. We have established an assay system for each of the biochemical activities of Rad51. Using these assays, the effects of BRCA2 on the biochemical activities of Rad51 will be examined.




Figure 3. Purified Rad51, Rad51B and Rad51C proteins

Final results:

(1) **Cloning, expression and purification of Rad51 paralog baculoviral proteins.** We have expressed the human Rad51 protein and two Rad51 paralogs, Rad51B and Rad51C, in insect cells Sf9 using the baculovirus system. These three proteins were further individually purified to homogeneity using sequential column chromatography (Figure 3).

(2) **Cloning, expression and purification of the BRC fragments.** We have employed the baculovirus strategies to express the BRC fragments of BRCA2, including BRC1-4, BRC5-8, and BRC1-8 domains (Figure 4). They encode proteins of 80-kDa, 65-kDa, and 138-kDa, respectively. Each recombinant

protein has been individually expressed in Sf9 cells (Figure 4) and the identity of the proteins was confirmed by Western Blotting using either α -BRC4 (aa1323-1346) or α -BRC5 (aa1651-1821) antibody (Figure 5) as well as α -His antibody. The BRC1-4 and BRC1-8 fragments have been further purified using a Ni-NTA column. Unfortunately, lots of proteolysis products were observed for both proteins after Ni-NTA purification. To solve the problem, we are currently co-expressing the individual fragment with Rad51 and hope that the interactions between BRCA2 and Rad51 will help stabilizing the BRCA2 structure and will make the co-purification of BRC1-4/Rad51 or BRC1-8/Rad51 complex possible.




Figure 4. Baculovirus expression of BRC1-4 fragment of human BRCA2 protein




Figure 5. Baculovirus expression of BRC1-4 and BRC1-8

2.1. To determine whether the BRCA2 protein mediates the DNA binding activity of Rad51. The BRCA2 protein has been shown to contain multiple Rad51-binding sites [3-6, 15], suggesting that BRCA2 may bind several molecules of Rad51 simultaneously and serve as a scaffold for Rad51 assembly to DNA binding as filaments. The evidence indicates the possibility of DNA binding of Rad51 mediated by BRCA2. Therefore, it will be determined whether BRCA2 protein mediates the DNA binding activity of Rad51.

We have established a gel shift assay to determine the DNA binding activity using [32 P]-labeled oligonucleotides. Using this assay, we have examined the DNA binding activity of Rad51, Rad51B and Rad51C proteins (Figure 6). We have shown that Rad51B and




Figure 6. DNA binding activity of human Rad51, Rad51B and Rad51C

Rad51C bind both single- and double-stranded DNA (ssDNA and dsDNA), and show preference for tailed dsDNA. The effects of the BRC1-4, BRC5-8 and BRC1-8 fragments on the DNA binding activity of Rad51 will be determined using this assay.

2.2. To determine whether the BRCA2 protein mediates the ATPase activity of Rad51. It has been shown that the BRCA2-binding region of human Rad51 (amino acids 98-339) is conserved in the *E. coli* homolog protein RecA. This region has been demonstrated to contain ATPase activity and is involved in oligomer formation and recombination. Therefore, whether BRCA2 functions to mediate the ATPase activity of Rad51 will be examined.




Figure 7. ATPase activity of Rad51, Rad51B and Rad51C in the presence of ssDNA

We have established an *in vitro* ATPase assay and determined the ATPase activity of the Rad51, Rad51B and Rad51C proteins (Figure 7). We have investigated the effect of the BRC1 domain of BRCA2 on the ATPase activity of Rad51. Various ratios of BRC1 and Rad51 were tested for the ATPase activity and an inhibitory effect was observed (Figure 8) — about 3.5 fold of inhibition was found with BRC1/Rad51 = 2. The suppression effect of the BRC1 domain on the ATPase activity of Rad51 suggests that the BRC1 domain of BRCA2 play a role in regulating the ATP binding and/or hydrolysis of Rad51.




Figure 8. Inhibition of the ATPase activity of Rad51 by BRC1 peptide

2.3. To determine whether the BRCA2 protein mediates the homologous pairing and strand transfer activity of Rad51. The key biochemical activity of Rad51 in the recombinational DNA repair process is to promote strand pairing and exchange between two homologous DNA strands [16-18]. It is very likely that the interaction between BRCA2 and Rad51 influences the strand transfer activity of Rad51 and leads to effects on homologous recombination.

We have established a DNA strand transfer assay using ssDNA 63mers and [³²P]-labeled dsDNA 32/32mers as the substrates. The DNA strand transfer activity of Rad51 was determined as a




Figure 9. DNA strand transfer activity

control. The strand transfer products (3'-tailed 63/32mer) were observed and the amount of product formation is dependent on the concentration of Rad51. We also demonstrated that Rad51C displays DNA strand transfer (Figure 9) in an ATP-independent manner (data not shown), while Rad51B shows no such activity. The effects of BRC1-4, BRC5-8 and BRC1-8 on the DNA strand transfer activity of Rad51 will be examined.

Conclusions and summary

To demonstrate that BRCA2 is an essential component of the Rad51-dependent DNA repair complex and understand how BRCA2 regulates homologous recombinational repair (HRR), we have made the N-terminal 6xHis-tagged baculoviral construct of BRC1-4, BRC5-8 and BRC1-8 fragments of BRCA2. These three individual fragments have been successfully co-expressed with Rad51, Rad51B and Rad51C in insect cells. The Ni-NTA pull-down experiments are currently carried out to determine the complex formation between these proteins.

The BRC1-4, BRC5-8 and BRC1-8 proteins were also individually expressed in insect cells. The baculovirus titers were amplified, so that the expression level of proteins were elevated and were able to be detected by Coomassie staining. Each protein was purified using a Ni-NTA column. We observed lots of proteolysis product of each protein after Ni-NTA purification, indicating that the structure of the BRC repeats of BRCA2 protein is not stable and the protein tends to degrade. To solve the problem, each fragment was co-expressed with Rad51 individually. We hope to be able to co-purify a stable BRC1-4/Rad51, BRC5-8/Rad51 or BRC1-8/Rad51 complex for *in vitro* biochemical activity assays.

We have established three *in vitro* biochemical assays for Rad51 in our laboratory, including DNA binding, ATPase and DNA strand exchange. We have successfully used these three assay systems to determine the activity of Rad51B and Rad51C protein and the results have been prepared in manuscript for publication. We have examined the effect of BRC1 domain on the ATPase activity of Rad51 and found that the BRC1 domain inhibits this activity. The result suggests that the BRC1 domain of BRCA2 plays a role in regulating the ATPase activity of Rad51. We will apply these three assay approaches for determining the effects of the BRC fragments (BRC1-4, BRC5-8, BRC1-8) on the activity of Rad51 when we obtained the purified BRC/Rad51 protein complex. We have received an Idea Award from DOD to continue the follow up research.

Key Research Accomplishments

1. The *in vitro* complex formation of Rad51-Rad51C-Rad51B was demonstrated.
2. The BRC1-4 and BRC1-8 fragments of BRCA2 protein were individually co-expressed with Rad51, Rad51B and Rad51C in insect cells.
3. The BRC1-4 and BRC1-8 fragments of BRCA2 were expressed and purified. However, the whole fragments tend to become proteolysis during the course of purification, indicative of an unstable property of the protein.
4. The BRC1 domain of BRCA2 inhibited the ATPase activity of human Rad51, suggesting that the BRC1 domain of BRCA2 plays a role in regulating the ATP binding and/or hydrolysis of Rad51.

Reportable Outcomes

1. A manuscript related to this project "In vitro activities and complex formation of the human Rad51B and Rad51C DNA repair proteins" was in preparation and is close to submit for publication.
2. A postdoctoral fellow, Dr. Olga Miroshnychenko was hired for this study.
3. A DOD Idea Award was approved for funding to continue the study.

References

1. Stratton, M.R. and Wooster, R., *Hereditary predisposition to breast cancer*. Curr Opin Genet Dev, 1996. **6**(1): p. 93-7.
2. Arver, B. *et al.*, *Hereditary breast cancer: a review*. Semin Cancer Biol, 2000. **10**(4): p. 271-88.
3. Wong, A.K.C. *et al.*, *RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2*. J Biol Chem, 1997. **272**(51): p. 31941-4.
4. Mizuta, R. *et al.*, *RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein*. Proc Natl Acad Sci U S A, 1997. **94**(13): p. 6927-32.
5. Sharan, S.K. *et al.*, *Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2*. Nature, 1997. **386**(6627): p. 804-10.
6. Katagiri, T. *et al.*, *Multiple possible sites of BRCA2 interacting with DNA repair protein RAD51*. Genes Chromosomes Cancer, 1998. **21**(3): p. 217-22.
7. Patel, K.J. *et al.*, *Involvement of Brca2 in DNA Repair*. Mol Cell, 1998. **1**(3): p. 347-57.
8. Abbott, D.W. *et al.*, *Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells*. J Natl Cancer Inst, 1998. **90**(13): p. 978-85.
9. Chen, P.L. *et al.*, *The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment*. Proc Natl Acad Sci U S A, 1998. **95**(9): p. 5287-92.
10. Bertwistle, D. *et al.*, *Nuclear location and cell cycle regulation of the BRCA2 protein*. Cancer Res, 1997. **57**(24): p. 5485-8.
11. Tavtigian, S.V. *et al.*, *The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds*. Nat Genet, 1996. **12**(3): p. 333-7.
12. Bork, P. *et al.*, *Internal repeats in the BRCA2 protein sequence*. Nat Genet, 1996. **13**(1): p. 22-3.
13. Yuan, S.S. *et al.*, *BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo*. Cancer Res, 1999. **59**(15): p. 3547-51.
14. Chen, C.F. *et al.*, *Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control*. J Biol Chem, 1999. **274**(46): p. 32931-5.

15. Morimatsu, M. *et al.*, *Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence*. *Cancer Res*, 1998. **58**(15): p. 3441-7.
16. Benson, F.E., Stasiak, A. and West, S.C., *Purification and characterization of the human Rad51 protein, an analogue of E. coli RecA*. *Embo J*, 1994. **13**(23): p. 5764-71.
17. Baumann, P., Benson, F.E. and West, S.C., *Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro*. *Cell*, 1996. **87**(4): p. 757-66.
18. Baumann, P. and West, S.C., *The human Rad51 protein: polarity of strand transfer and stimulation by hRP-A*. *Embo J*, 1997. **16**(17): p. 5198-206.
19. Schild, D. *et al.*, *Evidence for simultaneous protein interactions between human Rad51 paralogs*. *J Biol Chem*, 2000. **275**(22): p. 16443-9.
20. Takata, M. *et al.*, *The Rad51 paralog Rad51B promotes homologous recombinational repair*. *Mol Cell Biol*, 2000. **20**(17): p. 6476-82.
21. Braybrooke, J.P. *et al.*, *The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2*. *J Biol Chem*, 2000. **275**(37): p. 29100-6.
22. Cui, X. *et al.*, *The XRCC2 and XRCC3 repair genes are required for chromosome stability in mammalian cells*. *Mutat Res*, 1999. **434**(2): p. 75-88.
23. Brenneman, M. *et al.*, *XRCC3 is required for efficient repair of chromosome breaks by homologous recombination*. *Mutat Res*, 2000. **459**(2): p. 89-97.
24. Takata, M. *et al.*, *Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs*. *Mol Cell Biol*, 2001. **21**(8): p. 2858-66.
25. Raderschall, E. *et al.*, *Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage*. *Proc Natl Acad Sci U S A*, 1999. **96**(5): p. 1921-6.
26. Wiese, C. *et al.*, *Interactions involving the Rad51 paralogs Rad51C and XRCC3 in human cells*. *Nucleic Acids Res*. 2002, **30**(4), p.1001-1008.
27. Masson, J.-Y. *et al.*, *Identification and purification of two distinct complexes containing the five Rad51 paralogs*. *Genes Dev*. 2001, **15**, p. 3296-3307.
28. Liu, N., *et al.*, *Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells*. *Nucleic Acids Res*. 2002, **30**(4), p.1009-1015.
29. Davies, A.A. *et al.*, *Role of BRCA2 in control of the RAD51 recombination and DNA repair protein*. *Mol Cell*, 2001. **7**(2): p. 273-82.